MIRA INFORM REPORT

 

 

 

Report Date :

29.08.2013

 

IDENTIFICATION DETAILS

 

Name :

NATIONAL PHARMACEUTICAL INDUSTRIES CO.

 

 

Registered Office :

Al Rusayl Industrial Estate P.O.Box 120 Muscat, 124

 

 

Country :

Oman

 

 

Financials (as on) :

31.12.2012

 

 

Date of Incorporation :

14.02.1996

 

 

Legal Form :

Public Subsidiary

 

 

Line of Business :

Manufacture of pharmaceutical preparations

 

 

No. of Employees :

215

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Maximum Credit Limit:

765,000 USD

Status :

Satisfactory

Payment Behaviour :

No Complaints

Litigation :

Clear

 

 

NOTES :

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

 

ECGC Country Risk Classification List – March 31st, 2013

 

Country Name

Previous Rating

(31.12.2012)

Current Rating

(31.03.2013)

Oman

A2

A2

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

 

OMAN - ECONOMIC OVERVIEW

 

Oman is a middle-income economy that is heavily dependent on dwindling oil resources. Because of declining reserves and a rapidly growing labor force, Muscat has actively pursued a development plan that focuses on diversification, industrialization, and privatization, with the objective of reducing the oil sector's contribution to GDP to 9% by 2020 and creating more jobs to employ the rising numbers of Omanis entering the workforce. Tourism and gas-based industries are key components of the government's diversification strategy. However, increases in social welfare benefits, particularly since the Arab Spring, will challenge the government's ability to effectively balance its budget if oil revenues decline. By using enhanced oil recovery techniques, Oman succeeded in increasing oil production, giving the country more time to diversify, and the increase in global oil prices through 2011 provided the government greater financial resources to invest in non-oil sectors. In 2012, continued surpluses resulting from sustained high oil prices and increased enhanced oil recovery allowed the government to maintain growth in social subsidies and public sector job creation. However, the Sultan made widely reported statements indicating this would not be sustainable, and called for expanded efforts to support SME development and entrepreneurship. Government agencies and large oligarchic group companies heeded his call, announcing new initiatives to spin off non-essential functions to entrepreneurs, incubate new businesses, train and mentor up and coming business people, and provide financing for start-ups. In response to fast growth in household indebtedness, the Central Bank reduced the ceiling on personal interest loans from 8 to 7%, lowered mortgage rates, capped the percentage of consumer loans at 50% of borrower's salaries for personal loans and 60% for housing loans, and limited maximum repayment terms to 10 and 25 years respectively. In 2012 the Central Bank also issued final regulations governing Islamic banking and two full-fledged Islamic banks held oversubscribed IPOs while four traditional banks opened sharia-compliant Islamic windows.

Source : CIA


Company name and address

Top of Form

National Pharmaceutical Industries Co.

                                                                                                                                                    

 

Al Rusayl Industrial Estate

P.O.Box 120

 

Muscat, 124

Oman

 

 

Tel:

968-24-449090

Fax:

968-24-446431

 

npioman.com

 

Employees:

215

Company Type:

Public Subsidiary

Corporate Family:

2 Companies

Ultimate Parent:

Al Ritaj Holding KSCC

Traded:

Muscat Securities Market:

NPMI

Incorporation Date:

14-Feb-1996

Auditor:

Credit Limit

BDO

765,000 USD

Financials in:

 USD (mil)

Fiscal Year End:

31-Dec-2012

Reporting Currency:

Rial Omani

Annual Sales:

18.5  1

Net Income:

1.4

Total Assets:

37.2  2

Market Value:

13.0

 

(03-Jul-2013)

                                       

Business Description        

 

National Pharmaceutical Industries Co SAOG is an Oman-based joint stock company engaged in the manufacture of pharmaceutical products. The Company’s products include lipid lowering, cardio vascular, anti-bacterial, niche & mass, anti-allergic, non-steroidal anti-inflammatory, gastro intestinal, anti-diabetic, anti-depressant and analgesic antipyretic, among others. The Company’s facilities are spread over a 30,042.43 square meters plot of land, and consist of a non-beta lactum plant for the production of oral solids, liquids, drops, dry suspensions and sachets; a beta lactum plant, which produces capsules and dry suspension; a research and development laboratory, and a quality control laboratory. The Company is a subsidiary of Al Ritaj Holding Company, Kuwait, which holds 69.46% of the issued and paid up share capital of the Company. For the three months ended 31 March 2013, National Pharmaceutical Industries Co. revenues increased 19% to OMR2M. Net income increased 37% to OMR220K. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income benefited from Finance Charges decrease of 11% to OMR129K (expense).

          

Industry                                                                                                                                     

 

Industry

Pharmaceutical Manufacturing

ANZSIC 2006:

1841 - Human Pharmaceutical and Medicinal Product Manufacturing

ISIC Rev 4:

2100 - Manufacture of pharmaceuticals, medicinal chemical and botanical products

NACE Rev 2:

2120 - Manufacture of pharmaceutical preparations

NAICS 2012:

325412 - Pharmaceutical Preparation Manufacturing

UK SIC 2007:

2120 - Manufacture of pharmaceutical preparations

US SIC 1987:

2834 - Pharmaceutical Preparations

 

 

                      


Key Executives            

   

 

Name

Title

G. Sridhar

Chief Executive Officer and Secretary to the Board of Directors

Ghazi Omar Al Zubaidi

Non-Executive Independent Chairman of the Board

Khalifa Salman Al Mohannadi

Non-Executive Independent Member of the Board, representing Al Ritaj Holding Co.

Nayef Al Hajery

Director

Khaled Al Saeed

Director

   

Significant Developments                                                                                                                 

 

Topic

#*

Most Recent Headline

Date

Dividends

1

National Pharmaceutical Industries Co SAOG Recommends 14% Annual Cash Dividends For FY 2012

5-Mar-2013

      

Financial Summary                                                                                                                        

 

As of 31-Mar-2013

Key Ratios

Company

Industry

Current Ratio (MRQ)

3.00

2.09

Quick Ratio (MRQ)

2.28

1.48

Debt to Equity (MRQ)

0.97

0.43

Sales 5 Year Growth

18.92

4.13

Net Profit Margin (TTM) %

7.87

17.06

Return on Assets (TTM) %

4.03

9.59

Return on Equity (TTM) %

10.03

18.98

 

 

 

Stock Snapshot                                     

 

Traded: Muscat Securities Market: NPMI

 

As of 3-Jul-2013

   Financials in: OMR

Recent Price

0.10

 

EPS

0.01

52 Week High

0.11

 

Price/Sales

0.70

52 Week Low

0.10

 

Dividend Rate

0.01

Avg. Volume (mil)

0.0000

 

Price/Book

0.85

Market Value (mil)

5.00

 

 

 

 

Price % Change

Rel S&P 500%

4 Week

0.0000%

-3.07%

13 Week

0.0000%

-6.67%

 

 

1 - Profit & Loss Item Exchange Rate: USD 1 = OMR 0.3848844
2 - Balance Sheet Item Exchange Rate: USD 1 = OMR 0.385

 

 

Corporate Overview

 

Location
Al Rusayl Industrial Estate
P.O.Box 120
Muscat, 124
Oman

 

Tel:

968-24-449090

Fax:

968-24-446431

 

npioman.com

Quote Symbol - Exchange

NPMI - Muscat Securities Market

Sales OMR(mil):

7.1

Assets OMR(mil):

14.3

Employees:

215

Fiscal Year End:

31-Dec-2012

 

Industry:

Biotechnology and Drugs

Incorporation Date:

14-Feb-1996

Company Type:

Public Subsidiary

Quoted Status:

Quoted

 

Chief Executive Officer and Secretary to the Board of Directors:

G. Sridhar

 

Industry Codes

 

ANZSIC 2006 Codes:

1841

-

Human Pharmaceutical and Medicinal Product Manufacturing

 

ISIC Rev 4 Codes:

2100

-

Manufacture of pharmaceuticals, medicinal chemical and botanical products

 

NACE Rev 2 Codes:

2120

-

Manufacture of pharmaceutical preparations

2110

-

Manufacture of basic pharmaceutical products

 

NAICS 2012 Codes:

325412

-

Pharmaceutical Preparation Manufacturing

325411

-

Medicinal and Botanical Manufacturing

 

US SIC 1987:

2834

-

Pharmaceutical Preparations

2833

-

Medicinal Chemicals and Botanical Products

 

UK SIC 2007:

2120

-

Manufacture of pharmaceutical preparations

2110

-

Manufacture of basic pharmaceutical products

 

Business Description

National Pharmaceutical Industries Co SAOG is an Oman-based joint stock company engaged in the manufacture of pharmaceutical products. The Company’s products include lipid lowering, cardio vascular, anti-bacterial, niche & mass, anti-allergic, non-steroidal anti-inflammatory, gastro intestinal, anti-diabetic, anti-depressant and analgesic antipyretic, among others. The Company’s facilities are spread over a 30,042.43 square meters plot of land, and consist of a non-beta lactum plant for the production of oral solids, liquids, drops, dry suspensions and sachets; a beta lactum plant, which produces capsules and dry suspension; a research and development laboratory, and a quality control laboratory. The Company is a subsidiary of Al Ritaj Holding Company, Kuwait, which holds 69.46% of the issued and paid up share capital of the Company. For the three months ended 31 March 2013, National Pharmaceutical Industries Co. revenues increased 19% to OMR2M. Net income increased 37% to OMR220K. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income benefited from Finance Charges decrease of 11% to OMR129K (expense).

 

More Business Descriptions

Manufacture of pharmaceutical products

 

 

 

 

 

 

Financial Data

Financials in:

OMR(mil)

 

Revenue:

7.1

Net Income:

0.5

Assets:

14.3

Long Term Debt:

4.8

 

Total Liabilities:

8.4

 

Working Capital:

0.0

 

 

 

Date of Financial Data:

31-Dec-2012

 

1 Year Growth

11.7%

-49.4%

-0.9%

 

Market Data

Quote Symbol:

NPMI

Exchange:

Muscat Securities Market

Currency:

OMR

Stock Price:

0.1

Stock Price Date:

07-03-2013

52 Week Price Change %:

0.0

Market Value (mil):

5,000.0

 

SEDOL:

6635741

ISIN:

OM0000001939

 

 

Shareholders

 

 

Major Shareholders

Al Ritaj Holding KSCC, Kuwait (69.46%); Suhail Bahwan Group (30%)

 

 

 

 

Key Corporate Relationships

Auditor:

BDO

 

Auditor:

BDO, B D O Jawad Habib and Co

 

 

 

 

 

 

 

 

 

 

 

Corporate Structure News

 

National Pharmaceutical Industries Co.
Total Corporate Family Members: 2

 

 

Company Name

Company Type

Location

Country

Industry

Sales
(USD mil)

Employees

Al Ritaj Holding KSCC

Parent

 

 

 

 

 

National Pharmaceutical Industries Co.

Subsidiary

Muscat

Oman

Pharmaceutical Manufacturing

18.5

215

 



 

Executives Report

 

Board of Directors

 

Name

Title

Function

Ghazi Omar Al Zubaidi

 

Non-Executive Independent Chairman of the Board

Chairman

Biography:

Dr. Ghazi Omar Al Zubaidi serves as Non-Executive Independent Chairman of the Board for National Pharmaceutical Industries Co SAOG since April 29, 2008. Dr. Al Zubaidi is Advisor to H. E. Minister of Health for Hospitals Affairs.

 

Nayef Al Hajery

 

Director

Director/Board Member

 

Khalifa Salman Al Mohannadi

 

Non-Executive Independent Member of the Board, representing Al Ritaj Holding Co.

Director/Board Member

 

Biography:

Mr. Khalifa Salman Al Mohannadi serves as Non-Executive Independent Member of the Board of National Pharmaceutical Industries Co SAOG, representing Al Ritaj Holding Company since April 28, 2008. He is Member of Al Ritaj Holding Co. Mr. Al Mohannadi also served as Director at Pharo Pharma, Egypt and for Al- Ritaj Holding Co, Kuwait, as well as Chairman of the Board for Majdi Foods Co, Kuwait.

 

Khaled Al Saeed

 

Director

Director/Board Member

 

Khalid Abdullah Al Said

 

Non-Executive Independent Member of the Board

Director/Board Member

 

Biography:

Mr. Khalid Abdullah Al Said serves as Non-Executive Independent Member of the Board of National Pharmaceutical Industries Co SAOG since April 2012. He has experience in finance and investments.

 

Ali Hussein Mutlaq Al Sanad

 

Member of the Board

Director/Board Member

 

Omar Suhail Bahwan

 

Director

Director/Board Member

 

Amal Bint Suhail Bahwan

 

Non-Executive Independent Member of the Board

Director/Board Member

 

Biography:

Ms. Amal Bint Suhail Bahwan serves as Non-Executive Independent Member of the Board of National Pharmaceutical Industries Co SAOG. She is a businesswoman. Ms. Bahwan previously served as Chairperson at Oman Ceramics Co SAOG and as Director for Oman Oil Marketing Co SAOG.

 

Rahul Kar

 

Non-Executive Independent Member of the Board, representing Middle East Investment Co

Director/Board Member

 

Mahmoud Abdul Majid Zubaid

 

Non-Executive Member of the Board, representing Al Ritaj Investment Company

Director/Board Member

 

Biography:

Mr. Mahmoud Abdul Majid Zubaid serves as Non-Executive Member of the Board of National Pharmaceutical Industries Co SAOG, representing Al Ritaj Investment Company since December 2012. He has experience in Finance and business management.

 

 

Executives

 

Name

Title

Function

G. Sridhar

 

Chief Executive Officer and Secretary to the Board of Directors

Chief Executive Officer

Biography:

Mr. G. Sridhar serves as Chief Executive Officer and Secretary to the Board of Directors for National Pharmaceutical Industries Co SAOG since April 19, 2011. He holds a Masters Degree in Pharmacy. He has over 30 years experience in various pharmaceutical companies in product development, Quality Control, production, projects and general Management. His last assignments were at the position of General Manager of Pharmaceutical Companies.

 

 

Significant Developments

 

 

 

 

National Pharmaceutical Industries Co SAOG Recommends 14% Annual Cash Dividends For FY 2012

Mar 05, 2013


National Pharmaceutical Industries Co SAOG announced that its Board of Directors has recommended the Company to distribute a cash dividend of 14%, of the Share Capital, for the fiscal year ended December 31, 2012, subject to final approval of the shareholders of the Company in the Annual General Meeting.

 

 

 Annual Income Statement

 

Financials in: USD (mil)

 

Except for share items (millions) and per share items (actual units)

 

 

 

 

  Financial Glossary

 

 

 

31-Dec-2012

31-Dec-2011

31-Dec-2010

31-Dec-2009

31-Dec-2008

Period Length

12 Months

12 Months

12 Months

12 Months

12 Months

UpdateType/Date

Updated Normal
31-Dec-2012

Updated Normal
31-Dec-2011

Updated Normal
31-Dec-2010

Reclassified Normal
31-Dec-2010

Updated Normal
31-Dec-2008

Filed Currency

OMR

OMR

OMR

OMR

OMR

Exchange Rate (Period Average)

0.384884

0.385032

0.385008

0.384999

0.384956

Auditor

BDO

BDO

BDO

Moore Stephens

Moore Stephens

Auditor Opinion

Unqualified

Unqualified

Unqualified

Unqualified

Unqualified

 

 

 

 

 

 

    Net Sales

18.5

16.5

14.9

19.8

9.4

Revenue

18.5

16.5

14.9

19.8

9.4

Total Revenue

18.5

16.5

14.9

19.8

9.4

 

 

 

 

 

 

    Cost of Revenue

12.8

12.4

10.8

14.4

7.1

Cost of Revenue, Total

12.8

12.4

10.8

14.4

7.1

Gross Profit

5.6

4.2

4.1

5.3

2.3

 

 

 

 

 

 

    Selling/General/Administrative Expense

2.4

1.5

2.1

3.7

2.1

    Labor & Related Expense

0.7

0.6

0.7

0.5

-

Total Selling/General/Administrative Expenses

3.1

2.1

2.8

4.3

2.1

Research & Development

0.3

0.2

0.2

0.3

0.1

    Depreciation

0.1

0.1

0.1

0.1

1.3

Depreciation/Amortization

0.1

0.1

0.1

0.1

1.3

    Other, Net

-0.1

-0.1

-0.2

-0.3

-0.1

Other Operating Expenses, Total

-0.1

-0.1

-0.2

-0.3

-0.1

Total Operating Expense

16.2

14.6

13.6

18.7

10.5

 

 

 

 

 

 

Operating Income

2.3

1.9

1.3

1.0

-1.1

 

 

 

 

 

 

        Interest Expense - Non-Operating

-

-

-

-

-1.4

    Interest Expense, Net Non-Operating

-

-

-

-

-1.4

    Interest Income (Expense) - Net Non-Operating

-1.1

-1.1

-0.8

-0.9

0.4

Interest Income (Expense) - Net Non-Operating Total

-1.1

-1.1

-0.8

-0.9

-1.0

    Other Non-Operating Income (Expense)

0.4

0.4

-

-

-

Other, Net

0.4

0.4

-

-

-

Income Before Tax

1.6

1.2

0.5

0.1

-2.1

 

 

 

 

 

 

Total Income Tax

0.2

-1.5

0.0

0.0

0.0

Income After Tax

1.4

2.7

0.5

0.1

-2.1

 

 

 

 

 

 

Net Income Before Extraord Items

1.4

2.7

0.5

0.1

-2.1

Net Income

1.4

2.7

0.5

0.1

-2.1

 

 

 

 

 

 

Income Available to Common Excl Extraord Items

1.4

2.7

0.5

0.1

-2.1

 

 

 

 

 

 

Income Available to Common Incl Extraord Items

1.4

2.7

0.5

0.1

-2.1

 

 

 

 

 

 

Basic/Primary Weighted Average Shares

50.0

50.0

50.0

50.0

66.7

Basic EPS Excl Extraord Items

0.03

0.05

0.01

0.00

-0.03

Basic/Primary EPS Incl Extraord Items

0.03

0.05

0.01

0.00

-0.03

Dilution Adjustment

-

-

-

-

0.0

Diluted Net Income

1.4

2.7

0.5

0.1

-2.1

Diluted Weighted Average Shares

50.0

50.0

50.0

50.0

66.7

Diluted EPS Excl Extraord Items

0.03

0.05

0.01

0.00

-0.03

Diluted EPS Incl Extraord Items

0.03

0.05

0.01

0.00

-0.03

Dividends per Share - Common Stock Primary Issue

-

0.00

0.00

0.00

0.00

Gross Dividends - Common Stock

-

0.0

0.0

0.0

0.0

Interest Expense, Supplemental

-

-

-

0.9

1.4

Depreciation, Supplemental

1.5

1.5

1.4

1.3

1.3

Total Special Items

-

-

-

-

0.0

Normalized Income Before Tax

1.6

1.2

0.5

0.1

-2.1

 

 

 

 

 

 

Effect of Special Items on Income Taxes

-

-

-

-

0.0

Inc Tax Ex Impact of Sp Items

0.2

-1.5

0.0

0.0

0.0

Normalized Income After Tax

1.4

2.7

0.5

0.1

-2.1

 

 

 

 

 

 

Normalized Inc. Avail to Com.

1.4

2.7

0.5

0.1

-2.1

 

 

 

 

 

 

Basic Normalized EPS

0.03

0.05

0.01

0.00

-0.03

Diluted Normalized EPS

0.03

0.05

0.01

0.00

-0.03

Research & Development Exp, Supplemental

0.3

0.2

0.2

0.3

0.1

Normalized EBIT

2.3

1.9

1.3

1.0

-1.1

Normalized EBITDA

3.8

3.3

2.7

2.4

0.2

    Current Tax - Other

0.0

0.0

-

-

-

Current Tax - Total

0.0

0.0

-

-

-

    Deferred Tax - Other

0.2

-1.5

-

-

-

Deferred Tax - Total

0.2

-1.5

-

-

-

Income Tax - Total

0.2

-1.5

-

-

-

 



 

Annual Balance Sheet

Financials in: USD (mil)

 

  Financial Glossary

 

 

 

31-Dec-2012

31-Dec-2011

31-Dec-2010

31-Dec-2009

31-Dec-2008

UpdateType/Date

Updated Normal
31-Dec-2012

Updated Normal
31-Dec-2011

Updated Normal
31-Dec-2010

Restated Normal
31-Dec-2010

Updated Normal
31-Dec-2008

Filed Currency

OMR

OMR

OMR

OMR

OMR

Exchange Rate

0.385

0.385

0.385

0.38495

0.38505

Auditor

BDO

BDO

BDO

Moore Stephens

Moore Stephens

Auditor Opinion

Unqualified

Unqualified

Unqualified

Unqualified

Unqualified

 

 

 

 

 

 

    Cash & Equivalents

8.0

10.3

10.3

10.4

10.1

Cash and Short Term Investments

8.0

10.3

10.3

10.4

10.1

    Trade Accounts Receivable - Net

9.6

8.6

6.2

8.9

6.3

    Other Receivables

0.4

0.5

0.6

0.6

-

Total Receivables, Net

9.9

9.1

6.8

9.5

6.3

    Inventories - Finished Goods

2.0

0.8

1.0

-

0.4

    Inventories - Work In Progress

0.8

0.8

0.6

-

0.6

    Inventories - Raw Materials

3.8

2.9

2.7

-

4.1

Total Inventory

6.6

4.5

4.3

3.7

5.0

Prepaid Expenses

0.1

0.1

-

-

-

Total Current Assets

24.6

24.0

21.4

23.7

21.4

 

 

 

 

 

 

        Buildings

16.2

16.1

16.1

-

16.1

        Machinery/Equipment

10.2

9.8

8.9

-

7.7

        Construction in Progress

0.3

0.0

0.5

-

0.0

    Property/Plant/Equipment - Gross

26.7

25.9

25.4

-

23.8

    Accumulated Depreciation

-15.7

-14.2

-12.7

-

-10.0

Property/Plant/Equipment - Net

11.0

11.7

12.7

13.3

13.8

    Intangibles - Gross

0.4

0.4

-

-

-

    Accumulated Intangible Amortization

0.0

0.0

-

-

-

Intangibles, Net

0.3

0.4

0.3

0.3

0.0

    Deferred Income Tax - Long Term Asset

1.3

1.5

-

-

-

Other Long Term Assets, Total

1.3

1.5

-

-

-

Total Assets

37.2

37.6

34.3

37.2

35.3

 

 

 

 

 

 

Accounts Payable

1.6

1.6

2.0

2.7

2.1

Accrued Expenses

0.1

0.2

-

-

-

Notes Payable/Short Term Debt

7.1

8.3

7.3

9.7

9.4

Current Portion - Long Term Debt/Capital Leases

0.2

1.6

0.1

0.1

0.1

    Other Payables

0.0

0.3

0.6

0.8

-

Other Current liabilities, Total

0.0

0.3

0.6

0.8

-

Total Current Liabilities

9.0

12.0

9.9

13.3

11.6

 

 

 

 

 

 

    Long Term Debt

12.4

11.2

12.8

12.8

10.2

Total Long Term Debt

12.4

11.2

12.8

12.8

10.2

Total Debt

19.7

21.1

20.2

22.6

19.7

 

 

 

 

 

 

    Pension Benefits - Underfunded

0.5

0.4

0.4

0.3

0.2

    Other Long Term Liabilities

-

-

-

-

2.6

Other Liabilities, Total

0.5

0.4

0.4

0.3

2.8

Total Liabilities

21.9

23.6

23.1

26.5

24.6

 

 

 

 

 

 

    Common Stock

13.0

13.0

13.0

13.0

13.0

Common Stock

13.0

13.0

13.0

13.0

13.0

Retained Earnings (Accumulated Deficit)

2.3

1.0

-1.7

-2.3

-2.4

Total Equity

15.3

14.0

11.3

10.7

10.6

 

 

 

 

 

 

Total Liabilities & Shareholders’ Equity

37.2

37.6

34.3

37.2

35.3

 

 

 

 

 

 

    Shares Outstanding - Common Stock Primary Issue

50.0

50.0

50.0

50.0

50.0

Total Common Shares Outstanding

50.0

50.0

50.0

50.0

50.0

Number of Common Shareholders

888

888

888

-

896

Accumulated Intangible Amort, Suppl.

0.0

0.0

-

-

-

Total Long Term Debt, Supplemental

12.6

12.8

12.8

-

-

Long Term Debt Maturing within 1 Year

0.2

1.6

0.1

-

-

Long Term Debt Maturing in Year 2

1.6

1.6

1.6

-

-

Long Term Debt Maturing in Year 3

1.6

1.6

1.6

-

-

Long Term Debt Maturing in Year 4

1.6

1.6

1.6

-

-

Long Term Debt Maturing in Year 5

1.6

1.6

1.6

-

-

Long Term Debt Maturing in 2-3 Years

3.2

3.2

3.2

-

-

Long Term Debt Maturing in 4-5 Years

3.2

3.2

3.2

-

-

Long Term Debt Matur. in Year 6 & Beyond

6.0

4.8

6.4

-

-

Total Operating Leases, Supplemental

0.8

0.8

0.9

-

0.6

Operating Lease Payments Due in Year 1

0.1

0.1

0.1

-

0.0

Operating Lease Payments Due in Year 2

0.1

0.1

0.1

-

0.0

Operating Lease Payments Due in Year 3

0.1

0.1

0.1

-

0.0

Operating Lease Payments Due in Year 4

0.1

0.1

0.1

-

0.0

Operating Lease Payments Due in Year 5

0.1

0.1

0.1

-

0.0

Operating Lease Pymts. Due in 2-3 Years

0.2

0.2

0.2

-

0.1

Operating Lease Pymts. Due in 4-5 Years

0.2

0.2

0.2

-

0.1

Oper. Lse. Pymts. Due in Year 6 & Beyond

0.4

0.4

0.5

-

0.4

 

 

 

Annual Cash Flows

Financials in: USD (mil)

 

  Financial Glossary

 

 

 

31-Dec-2012

31-Dec-2011

31-Dec-2010

31-Dec-2009

31-Dec-2008

Period Length

12 Months

12 Months

12 Months

12 Months

12 Months

UpdateType/Date

Updated Normal
31-Dec-2012

Updated Normal
31-Dec-2011

Updated Normal
31-Dec-2010

Restated Normal
31-Dec-2010

Updated Normal
31-Dec-2008

Filed Currency

OMR

OMR

OMR

OMR

OMR

Exchange Rate (Period Average)

0.384884

0.385032

0.385008

0.384999

0.384956

Auditor

BDO

BDO

BDO

Moore Stephens

Moore Stephens

Auditor Opinion

Unqualified

Unqualified

Unqualified

Unqualified

Unqualified

 

 

 

 

 

 

Cash Receipts

-

-

-

-

5.2

Cash Payments

-

-

-

-

-10.0

Cash Interest Paid

-

-

-

-

-1.0

    Accounts Receivable

-0.9

-2.4

2.7

-3.2

-

    Inventories

-2.0

-0.2

-0.6

1.3

-

    Other Assets

0.2

-1.5

-

-

-

    Payable/Accrued

-0.4

-0.4

-1.0

1.4

-

    Other Liabilities

0.0

0.0

0.0

0.0

-

    Other Operating Cash Flow

3.7

4.9

2.8

2.5

0.0

Changes in Working Capital

0.6

0.3

4.0

2.0

0.0

Cash from Operating Activities

0.6

0.3

4.0

2.0

-5.9

 

 

 

 

 

 

    Purchase of Fixed Assets

-0.8

-0.4

-0.8

-0.8

-0.1

    Purchase/Acquisition of Intangibles

0.0

-0.2

0.0

-0.3

-

Capital Expenditures

-0.8

-0.6

-0.9

-1.0

-0.1

    Sale of Fixed Assets

-

-

-

0.0

0.0

    Other Investing Cash Flow

-

-

-

-

-9.3

Other Investing Cash Flow Items, Total

-

-

-

0.0

-9.3

Cash from Investing Activities

-0.8

-0.6

-0.9

-1.0

-9.4

 

 

 

 

 

 

    Other Financing Cash Flow

-0.7

-0.7

-0.8

-0.9

3.0

Financing Cash Flow Items

-0.7

-0.7

-0.8

-0.9

3.0

        Sale/Issuance of Common

-

-

-

-

12.8

    Common Stock, Net

-

-

-

-

12.8

Issuance (Retirement) of Stock, Net

-

-

-

-

12.8

    Short Term Debt, Net

2.0

0.0

-0.2

-0.2

-

        Long Term Debt Reduction

-0.2

-0.1

-0.1

-0.1

-0.1

    Long Term Debt, Net

-1.4

1.0

-2.5

0.3

-0.1

Issuance (Retirement) of Debt, Net

0.6

0.9

-2.6

0.1

-0.1

Cash from Financing Activities

-0.1

0.2

-3.4

-0.9

15.8

 

 

 

 

 

 

Net Change in Cash

-0.2

-0.1

-0.3

0.1

0.5

 

 

 

 

 

 

Net Cash - Beginning Balance

0.5

0.6

0.9

0.8

-4.1

Net Cash - Ending Balance

0.2

0.5

0.6

0.9

-3.6

 

 

Annual Income Statement

 

Financials in: USD (mil)

 

Except for share items (millions) and per share items (actual units)

 

 

 

 

 

 

 

 

31-Dec-2012

31-Dec-2011

31-Dec-2010

31-Dec-2009

31-Dec-2008

Period Length

12 Months

12 Months

12 Months

12 Months

12 Months

UpdateType/Date

Updated Normal
31-Dec-2012

Updated Normal
31-Dec-2011

Updated Normal
31-Dec-2010

Reclassified Normal
31-Dec-2010

Updated Normal
31-Dec-2008

Filed Currency

OMR

OMR

OMR

OMR

OMR

Exchange Rate (Period Average)

0.384884

0.385032

0.385008

0.384999

0.384956

Auditor

BDO

BDO

BDO

Moore Stephens

Moore Stephens

Auditor Opinion

Unqualified

Unqualified

Unqualified

Unqualified

Unqualified

 

 

 

 

 

 

    Revenue

18.5

16.5

14.9

19.8

9.4

Total Revenue

18.5

16.5

14.9

19.8

9.4

 

 

 

 

 

 

    Cost of Sales

12.8

12.4

10.8

14.4

7.1

    Other Income

-0.1

-0.1

-0.2

-0.3

-0.1

    Product Development Expenses

0.3

0.2

0.2

0.3

0.1

    Salaries and Staff Costs

0.7

0.6

0.7

0.5

-

    Depreciation

0.1

0.1

0.1

0.1

1.3

    Administrative and General Expenses

2.4

1.5

2.1

3.7

2.1

Total Operating Expense

16.2

14.6

13.6

18.7

10.5

 

 

 

 

 

 

    Finance Charges (Government Grant)

-1.1

-1.1

-0.8

-0.9

0.4

    Governement Grant Income

0.4

0.4

-

-

-

    Interest Expense

-

-

-

-

-1.4

Net Income Before Taxes

1.6

1.2

0.5

0.1

-2.1

 

 

 

 

 

 

Provision for Income Taxes

0.2

-1.5

0.0

0.0

0.0

Net Income After Taxes

1.4

2.7

0.5

0.1

-2.1

 

 

 

 

 

 

Net Income Before Extra. Items

1.4

2.7

0.5

0.1

-2.1

Net Income

1.4

2.7

0.5

0.1

-2.1

 

 

 

 

 

 

Income Available to Com Excl ExtraOrd

1.4

2.7

0.5

0.1

-2.1

 

 

 

 

 

 

Income Available to Com Incl ExtraOrd

1.4

2.7

0.5

0.1

-2.1

 

 

 

 

 

 

Basic Weighted Average Shares

50.0

50.0

50.0

50.0

66.7

Basic EPS Excluding ExtraOrdinary Items

0.03

0.05

0.01

0.00

-0.03

Basic EPS Including ExtraOrdinary Items

0.03

0.05

0.01

0.00

-0.03

Dilution Adjustment

-

-

-

-

0.0

Diluted Net Income

1.4

2.7

0.5

0.1

-2.1

Diluted Weighted Average Shares

50.0

50.0

50.0

50.0

66.7

Diluted EPS Excluding ExtraOrd Items

0.03

0.05

0.01

0.00

-0.03

Diluted EPS Including ExtraOrd Items

0.03

0.05

0.01

0.00

-0.03

DPS-Ordinary Shares

-

0.00

0.00

0.00

0.00

Gross Dividends - Common Stock

-

0.0

0.0

0.0

0.0

Normalized Income Before Taxes

1.6

1.2

0.5

0.1

-2.1

 

 

 

 

 

 

Inc Tax Ex Impact of Sp Items

0.2

-1.5

0.0

0.0

0.0

Normalized Income After Taxes

1.4

2.7

0.5

0.1

-2.1

 

 

 

 

 

 

Normalized Inc. Avail to Com.

1.4

2.7

0.5

0.1

-2.1

 

 

 

 

 

 

Basic Normalized EPS

0.03

0.05

0.01

0.00

-0.03

Diluted Normalized EPS

0.03

0.05

0.01

0.00

-0.03

Depreciation

1.5

1.5

1.4

1.3

1.3

Product Development Expenses

0.3

0.2

0.2

0.3

0.1

Interest Expenses

-

-

-

0.9

1.4

    Current Tax

0.0

0.0

-

-

-

Current Tax - Total

0.0

0.0

-

-

-

    Deferred Income Tax

0.3

-1.9

-

-

-

    Defrred Tax Liability

-0.1

0.4

-

-

-

Deferred Tax - Total

0.2

-1.5

-

-

-

Income Tax - Total

0.2

-1.5

-

-

-

 

 

 

Annual Balance Sheet

Financials in: USD (mil)

 

 

 

31-Dec-2012

31-Dec-2011

31-Dec-2010

31-Dec-2009

31-Dec-2008

UpdateType/Date

Updated Normal
31-Dec-2012

Updated Normal
31-Dec-2011

Updated Normal
31-Dec-2010

Restated Normal
31-Dec-2010

Updated Normal
31-Dec-2008

Filed Currency

OMR

OMR

OMR

OMR

OMR

Exchange Rate

0.385

0.385

0.385

0.38495

0.38505

Auditor

BDO

BDO

BDO

Moore Stephens

Moore Stephens

Auditor Opinion

Unqualified

Unqualified

Unqualified

Unqualified

Unqualified

 

 

 

 

 

 

    Raw Materials and Packaging Materials

3.8

2.9

2.7

-

4.1

    Work in Progress

0.8

0.8

0.6

-

0.6

    Finished Goods

2.0

0.8

1.0

-

0.4

    Inventories

-

-

-

3.7

-

    Accounts Receivables

8.3

7.5

5.5

8.4

5.9

    Prepayments

0.1

0.1

-

-

-

    Other Receivables

0.4

0.5

0.6

0.6

-

    Amounts due from Related Parties

1.3

1.2

0.7

0.5

0.3

    Cash and Bank Balance

0.2

0.5

0.6

0.9

0.8

    Fixed Deposits

7.8

9.8

9.8

9.6

9.4

Total Current Assets

24.6

24.0

21.4

23.7

21.4

 

 

 

 

 

 

    Buildings

16.2

16.1

16.1

-

16.1

    Plant and Equipment

9.3

9.0

8.1

-

7.1

    Furniture Fixtures and Office Equipment

0.6

0.5

0.5

-

0.3

    Office Equipments

0.2

0.2

0.2

-

0.2

    Motor Vehicles

0.1

0.1

0.1

-

0.1

    Capital Work in Progress

0.3

0.0

0.5

-

0.0

    Accumulated Depreciation

-15.7

-14.2

-12.7

-

-10.0

    Property, Plant and Equipment

-

-

-

13.3

-

    Intangible assets

-

-

0.3

0.3

0.0

    Intangible Gross

0.4

0.4

-

-

-

    Accumulated Amortization

0.0

0.0

-

-

-

    Deferred Tax Assets

1.3

1.5

-

-

-

Total Assets

37.2

37.6

34.3

37.2

35.3

 

 

 

 

 

 

    Accounts payable & Other Accruals

1.5

1.5

1.9

2.6

2.0

    Other Payables

0.0

0.3

0.6

0.8

-

    Accrued expenses

0.1

0.2

-

-

-

    Amounts Due to Related Parties

0.1

0.1

0.1

0.1

0.1

    Bank Borrowings

7.1

8.3

7.3

9.7

9.4

    Current Portion of Government Loan

0.2

1.6

0.1

0.1

0.1

Total Current Liabilities

9.0

12.0

9.9

13.3

11.6

 

 

 

 

 

 

    Government Soft Loan

12.4

11.2

12.8

12.8

10.2

Total Long Term Debt

12.4

11.2

12.8

12.8

10.2

 

 

 

 

 

 

    Provision for Staff terminal Benefits

0.5

0.4

0.4

0.3

0.2

    Deferred Government Grants

-

-

-

-

2.6

Total Liabilities

21.9

23.6

23.1

26.5

24.6

 

 

 

 

 

 

    Share Capital

13.0

13.0

13.0

13.0

13.0

    Legal Reserve

0.5

0.3

0.1

0.0

0.0

    Special Reserve

0.0

0.0

0.0

0.0

0.0

    Accumulated Loss

1.8

0.6

-1.8

-2.3

-2.4

Total Equity

15.3

14.0

11.3

10.7

10.6

 

 

 

 

 

 

Total Liabilities & Shareholders' Equity

37.2

37.6

34.3

37.2

35.3

 

 

 

 

 

 

    S/O-Ordinary Shares

50.0

50.0

50.0

50.0

50.0

Total Common Shares Outstanding

50.0

50.0

50.0

50.0

50.0

Accumulated Intangible Amort, Suppl.

0.0

0.0

-

-

-

Number of Shareholders

888

888

888

-

896

Long Term Debt Maturing within 1 Year

0.2

1.6

0.1

-

-

Long Term Debt Maturing in 1-5 Years

6.4

6.4

6.4

-

-

Long Term Debt Maturing after 5 Years

6.0

4.8

6.4

-

-

Total Long Term Debt, Supplemental

12.6

12.8

12.8

-

-

Lease Due Not Later than 1 Yr

0.1

0.1

0.1

-

0.0

Lease Due Between 1-5 Yrs

0.3

0.3

0.3

-

0.2

Lease Due After 5 Yrs

0.4

0.4

0.5

-

0.4

Total Operating Leases, Supplemental

0.8

0.8

0.9

-

0.6

 

 

Annual Cash Flows

Financials in: USD (mil)

 

 

 

31-Dec-2012

31-Dec-2011

31-Dec-2010

31-Dec-2009

31-Dec-2008

Period Length

12 Months

12 Months

12 Months

12 Months

12 Months

UpdateType/Date

Updated Normal
31-Dec-2012

Updated Normal
31-Dec-2011

Updated Normal
31-Dec-2010

Restated Normal
31-Dec-2010

Updated Normal
31-Dec-2008

Filed Currency

OMR

OMR

OMR

OMR

OMR

Exchange Rate (Period Average)

0.384884

0.385032

0.385008

0.384999

0.384956

Auditor

BDO

BDO

BDO

Moore Stephens

Moore Stephens

Auditor Opinion

Unqualified

Unqualified

Unqualified

Unqualified

Unqualified

 

 

 

 

 

 

    Cash Receipts

-

-

-

-

5.2

    Cash Payments

-

-

-

-

-10.0

    Net Profit for the Year

1.4

2.7

0.5

0.1

-

    Depreciation

1.5

1.5

1.4

1.3

-

    Fair Value Adj. Intangible Assets

0.0

0.0

0.0

0.0

-

    Profit on Sale of PPE

-

-

0.0

0.0

-

    Finance Costs

0.7

0.7

0.8

0.9

-

    Staff Terminal Benefits

0.1

0.0

0.1

0.1

-

    Cash Interest Paid

-

-

-

-

-1.0

    Inventories

-2.0

-0.2

-0.6

1.3

-

    Deferred Tax Assets

0.2

-1.5

-

-

-

    Receivables and Prepayments

-0.7

-2.0

3.0

-3.1

-

    Payables and Accruals

-0.4

-0.4

-1.0

1.4

-

    Related Parties

-0.2

-0.4

-0.2

-0.1

-

    Due to Related Parties

0.0

0.0

0.0

0.0

-

    BOD's Remuneration

-

-

-

-

0.0

Cash from Operating Activities

0.6

0.3

4.0

2.0

-5.9

 

 

 

 

 

 

    Additions to Property, Plant and Equip.

-0.8

-0.4

-0.8

-0.8

-0.1

    Purchase of Intangibles

0.0

-0.2

0.0

-0.3

-

    Property, Plant, Equipment

-

-

-

0.0

0.0

    Movement in Short Term Deposits

-

-

-

-

-9.4

    Interest on Short Term Deposits

-

-

-

-

0.1

Cash from Investing Activities

-0.8

-0.6

-0.9

-1.0

-9.4

 

 

 

 

 

 

    Governement Soft Loan

-0.2

-0.1

-0.1

-0.1

-0.1

    Additional Capital

-

-

-

-

12.8

    ST Loan from Bank

2.0

0.0

-0.2

-0.2

-

    Net Bank Borrowings

-1.2

1.0

-2.4

0.3

-

    Finance Costs Paid

-0.7

-0.7

-0.8

-0.9

-

    Share Applic. Money Pending Allotment

-

-

-

-

3.0

    Net Balance of Share Issue Charges

-

-

-

-

0.0

Cash from Financing Activities

-0.1

0.2

-3.4

-0.9

15.8

 

 

 

 

 

 

Net Change in Cash

-0.2

-0.1

-0.3

0.1

0.5

 

 

 

 

 

 

Net Cash - Beginning Balance

0.5

0.6

0.9

0.8

-4.1

Net Cash - Ending Balance

0.2

0.5

0.6

0.9

-3.6

 

 

Financial Health

 

Financials in: USD (mil)

 

Except for share items (millions) and per share items (actual units)

 

 

Key Indicators USD (mil)

 

Quarter
Ending
31-Mar-2013

Quarter
Ending
Yr Ago

Annual
Year End
31-Dec-2012

1 Year
Growth

3 Year
Growth

5 Year
Growth

Total Revenue1 (?)

5.2

18.54%

18.5

11.73%

-2.25%

18.92%

Research & Development1 (?)

-

-

0.3

19.82%

-0.30%

13.10%

Operating Income1 (?)

0.7

22.88%

2.3

23.34%

30.28%

-

Income Available to Common Excl Extraord Items1 (?)

0.6

37.25%

1.4

-49.45%

133.10%

-

Basic EPS Excl Extraord Items1 (?)

0.01

37.50%

0.03

-49.28%

135.88%

-

Capital Expenditures2 (?)

0.1

-51.82%

0.8

36.60%

-7.54%

121.22%

Cash from Operating Activities2 (?)

2.2

-

0.6

116.98%

-31.43%

-

Free Cash Flow (?)

2.1

-

-0.2

-

-

-

Total Assets3 (?)

36.3

-6.98%

37.2

-0.90%

0.05%

11.88%

Total Liabilities3 (?)

20.4

-17.23%

21.9

-7.17%

-6.06%

0.64%

Total Long Term Debt3 (?)

9.7

9.10%

12.4

10.92%

-1.13%

13.20%

Total Common Shares Outstanding3 (?)

50.0

0.00%

50.0

0.00%

0.00%

45.84%

1-ExchangeRate: OMR to USD Average for Period

0.384934

 

0.384884

 

 

 

2-ExchangeRate: OMR to USD Average for Period

0.384934

 

0.384884

 

 

 

3-ExchangeRate: OMR to USD Period End Date

0.384900

 

0.385000

 

 

 

Key Ratios

 

31-Dec-2012

31-Dec-2011

31-Dec-2010

31-Dec-2009

31-Dec-2008

Profitability

Gross Margin (?)

30.43%

25.22%

27.70%

26.90%

24.45%

Operating Margin (?)

12.48%

11.31%

8.66%

5.27%

-11.80%

Pretax Margin (?)

8.73%

7.08%

3.54%

0.54%

-22.71%

Net Profit Margin (?)

7.38%

16.31%

3.54%

0.54%

-22.71%

Financial Strength

Current Ratio (?)

2.73

1.99

2.16

1.78

1.85

Long Term Debt/Equity (?)

0.81

0.80

1.13

1.20

0.96

Total Debt/Equity (?)

1.29

1.51

1.79

2.11

1.85

Interest Coverage (?)

2.12

1.66

1.69

1.12

-

Management Effectiveness

Return on Assets (?)

3.64%

7.49%

1.48%

0.30%

-7.54%

Return on Equity (?)

9.31%

21.37%

4.80%

1.01%

-40.10%

Efficiency

Receivables Turnover (?)

1.94

2.08

1.83

2.51

1.98

Inventory Turnover (?)

2.32

2.81

2.69

3.31

1.82

Asset Turnover (?)

0.49

0.46

0.42

0.55

0.33

Market Valuation USD (mil)

P/E (TTM) (?)

8.56

.

Enterprise Value2 (?)

20.1

Price/Sales (TTM) (?)

0.67

.

Enterprise Value/Revenue (TTM) (?)

1.04

Price/Book (MRQ) (?)

0.82

.

Enterprise Value/EBITDA (TTM) (?)

5.09

Market Cap as of 03-Jul-20131 (?)

13.0

.

 

 

1-ExchangeRate: OMR to USD on 3-Jul-2013

0.384850

 

 

 

2-ExchangeRate: OMR to USD on 31-Mar-2013

0.384900

 

 

 

 

 

Annual Ratios

Financials in: USD (mil)

 

Except for share items (millions) and per share items (actual units)

 

 

 



 

 

31-Dec-2012

31-Dec-2011

31-Dec-2010

31-Dec-2009

31-Dec-2008

Financial Strength

Current Ratio (?)

2.73

1.99

2.16

1.78

1.85

Quick/Acid Test Ratio (?)

1.99

1.61

1.73

1.50

1.42

Working Capital1 (?)

15.6

12.0

11.5

10.4

9.8

Long Term Debt/Equity (?)

0.81

0.80

1.13

1.20

0.96

Total Debt/Equity (?)

1.29

1.51

1.79

2.11

1.85

Long Term Debt/Total Capital (?)

0.35

0.32

0.41

0.38

0.34

Total Debt/Total Capital (?)

0.56

0.60

0.64

0.68

0.65

Interest Coverage (?)

2.12

1.66

1.69

1.12

-

Payout Ratio (?)

-

0.00%

0.00%

0.00%

0.00%

Effective Tax Rate (?)

15.46%

-130.35%

0.00%

0.00%

-

Total Capital1 (?)

35.0

35.1

31.4

33.3

30.3

 

 

 

 

 

 

Efficiency

Asset Turnover (?)

0.49

0.46

0.42

0.55

0.33

Inventory Turnover (?)

2.32

2.81

2.69

3.31

1.82

Days In Inventory (?)

157.65

130.11

135.73

110.44

200.96

Receivables Turnover (?)

1.94

2.08

1.83

2.51

1.98

Days Receivables Outstanding (?)

188.46

175.44

199.05

145.48

184.62

 

 

 

 

 

 

Profitability

Gross Margin (?)

30.43%

25.22%

27.70%

26.90%

24.45%

Operating Margin (?)

12.48%

11.31%

8.66%

5.27%

-11.80%

EBITDA Margin (?)

20.63%

20.09%

18.15%

12.10%

2.30%

EBIT Margin (?)

12.48%

11.31%

8.66%

5.27%

-11.80%

Pretax Margin (?)

8.73%

7.08%

3.54%

0.54%

-22.71%

Net Profit Margin (?)

7.38%

16.31%

3.54%

0.54%

-22.71%

R&D Expense/Revenue (?)

1.35%

1.26%

1.36%

1.28%

1.41%

COGS/Revenue (?)

69.57%

74.78%

72.30%

73.10%

75.55%

SG&A Expense/Revenue (?)

16.78%

12.85%

18.73%

21.67%

21.93%

 

 

 

 

 

 

Management Effectiveness

Return on Assets (?)

3.64%

7.49%

1.48%

0.30%

-7.54%

Return on Equity (?)

9.31%

21.37%

4.80%

1.01%

-40.10%

 

 

 

 

 

 

Valuation

Free Cash Flow/Share2 (?)

0.00

-0.01

0.06

0.02

-0.12

Operating Cash Flow/Share 2 (?)

0.01

0.01

0.08

0.04

-0.12

1-ExchangeRate: OMR to USD Period End Date

0.385

0.385

0.385

0.38495

0.38505

2-ExchangeRate: OMR to USD Average for Period

0.385

0.385

0.385

0.38495

0.38505

 

Current Market Multiples

Market Cap/Earnings (TTM) (?)

8.56

Market Cap/Equity (MRQ) (?)

0.82

Market Cap/Revenue (TTM) (?)

0.67

Market Cap/EBIT (TTM) (?)

5.33

Market Cap/EBITDA (TTM) (?)

3.29

Enterprise Value/Earnings (TTM) (?)

13.23

Enterprise Value/Equity (MRQ) (?)

1.26

Enterprise Value/Revenue (TTM) (?)

1.04

Enterprise Value/EBIT (TTM) (?)

8.23

Enterprise Value/EBITDA (TTM) (?)

5.09

 

 

 

 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.68.36

UK Pound

1

Rs.106.03

Euro

1

Rs.91.47

 

 

INFORMATION DETAILS

 

Report Prepared by :

PRL

 

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

--

NB

New Business

 

--

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                  Payment record (10%)

Credit history (10%)                   Market trend (10%)                                Operational size (10%)

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.